Shares of Baxter International Inc (NYSE:BAX) ended Friday session in green amid volatile trading. The shares closed up +0.12 points or 0.26% at $46.28 with 3.08 million shares getting traded. Post opening the session at $46.38, the shares hit an intraday low of $46.08 and an intraday high of $46.44 and the price vacillated in this range throughout the day. The company has a market cap of $24.87 billion and the numbers of outstanding shares have been calculated to be 543.89 million shares.
Baxter International Inc (BAX) on August 25, 2016 announced an agreement to provide patients with the latest advancements in peritoneal dialysis, hemodialysis and continuous renal replacement therapy.
Under the four-year agreement, Satellite Healthcare plans to offer AMIA Automated Peritoneal Dialysis (APD) system with SHARESOURCE to peritoneal dialysis (PD) patients, and integrate REVACLEAR into its high-flux hemodialysis therapy offering at its 80 Satellite Dialysis and Satellite WellBound home dialysis centers that serve more than 7,000 patients nationwide. Details of the agreement were not disclosed.
”Baxter and Satellite Healthcare share a common goal to provide patients with a better dialysis experience,” said Giuseppe Accogli, corporate vice president and president, Baxter Renal. ”We are pleased to continue our relationship with an organization that is clearly leading the way and revolutionizing how kidney disease patients are cared for in the U.S.”
Shares of Great Basin Scientific Inc (NASDAQ:GBSN) ended Friday session in red amid volatile trading. The shares closed down -0.009 points or -4.50% at $0.191 with 6.12 million shares getting traded. Post opening the session at $0.20, the shares hit an intraday low of $0.18 and an intraday high of $0.20 and the price vacillated in this range throughout the day. The company has a market cap of $9.11 million and the numbers of outstanding shares have been calculated to be 47.92 million shares.
Great Basin Scientific Inc (GBSN) on August 11, 2016 reported financial results for the second quarter ended June 30, 2016.
Second Quarter 2016 Financial Results and Business Highlights
- Revenue increased 38.7% to $728,957 compared with a year ago
- Total installed customer base up 126.1% over last year to 260
- Assay adoption rate (assays placed) up 18.2% over last year
- Product line to double in third quarter; initial impact to revenues expected in fourth quarter
- Closed $6 million public offering of units; secured $75 million convertible note
- Hired Mike Blitz, vice president of US Sales, to lead expansion of sales activities including the commercial launch of the Company’s Shiga Toxin Direct test and Staph ID/R Blood Culture panel
“We continued to make significant strides in executing our strategic initiatives including growing our customer base, expanding use of assays within our customer base, and in meeting our product development objectives,” said Ryan Ashton, Co-founder and Chief Executive Officer. “Going forward, we’re excited about the commercial launch of our Shiga Toxin Direct Test and Staph ID/R Panel which will double our line of FDA-cleared products and will aid in building our total revenue base, increasing sales per customer figures and reducing seasonality in our revenue stream.”